CEO Chris Viehbacher's future may not have been on the Sanofi board's agenda Monday. But it was on Wednesday. The directors issued a statement after an 8 a.m. meeting, the gist of which is this: At Sanofi ($SNY), he has none. After a few tense days, with talk of a potential ouster swirling, the board "decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi," t...

Multinational pharma companies have been targeting China for years with an eye on its aging population, expanding middle class and growing incidence of chronic maladies like diabetes. So how are Germany's leading pharmas, Bayer and Merck KGaA, carving out an edge for themselves? Reputation, tech-sharing and cold, hard cash. By playing up their track record for quality manufacturing, bringing prop...

What about that diabetes price war? When Sanofi ($SNY) announced that its franchise would suffer next year because of U.S. payer contracts, that was the natural follow-up question. If Sanofi had to boost its rebates to win coverage--which the company admits it did--then that means its rivals, including Eli Lilly ($LLY) and Novo Nordisk ($NVO) have, too. And with that payer pressure unlikely to ea...

Prince Fahd bin Salman Charity Association for Renal Failure Patients Care said on Saturday the association has spent more than SR234 million for all renal failure patients enrolled in the hemodialysis program that has been launched in 1428 AH. Prince Abdul Aziz bin Salman, supervisor of the association, said: "The association pays for the treatment of renal failure patients to medical centers ...